@article{SiegmundZaitsevaWajant2023, author = {Siegmund, Daniela and Zaitseva, Olena and Wajant, Harald}, title = {Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signaling}, series = {Frontiers in Cell and Developmental Biology}, volume = {11}, journal = {Frontiers in Cell and Developmental Biology}, issn = {2296-634X}, doi = {10.3389/fcell.2023.1267837}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-354304}, year = {2023}, abstract = {Tumor necrosis factor (TNF) receptor 1 (TNFR1), TNFR2 and fibroblast growth factor-inducible 14 (Fn14) belong to the TNF receptor superfamily (TNFRSF). From a structural point of view, TNFR1 is a prototypic death domain (DD)-containing receptor. In contrast to other prominent death receptors, such as CD95/Fas and the two TRAIL death receptors DR4 and DR5, however, liganded TNFR1 does not instruct the formation of a plasma membrane-associated death inducing signaling complex converting procaspase-8 into highly active mature heterotetrameric caspase-8 molecules. Instead, liganded TNFR1 recruits the DD-containing cytoplasmic signaling proteins TRADD and RIPK1 and empowers these proteins to trigger cell death signaling by cytosolic complexes after their release from the TNFR1 signaling complex. The activity and quality (apoptosis versus necroptosis) of TNF-induced cell death signaling is controlled by caspase-8, the caspase-8 regulatory FLIP proteins, TRAF2, RIPK1 and the RIPK1-ubiquitinating E3 ligases cIAP1 and cIAP2. TNFR2 and Fn14 efficiently recruit TRAF2 along with the TRAF2 binding partners cIAP1 and cIAP2 and can thereby limit the availability of these molecules for other TRAF2/cIAP1/2-utilizing proteins including TNFR1. Accordingly, at the cellular level engagement of TNFR2 or Fn14 inhibits TNFR1-induced RIPK1-mediated effects reaching from activation of the classical NFκB pathway to induction of apoptosis and necroptosis. In this review, we summarize the effects of TNFR2- and Fn14-mediated depletion of TRAF2 and the cIAP1/2 on TNFR1 signaling at the molecular level and discuss the consequences this has in vivo.}, language = {en} } @phdthesis{Shaikh2024, author = {Shaikh, Muhammad Haroon}, title = {Nicht-h{\"a}matopoetische lymphoide Stromazellen aktivieren alloreaktive CD4\(^+\) T-Zellen in der Initiierung der akuten Graft-versus-Host Disease}, doi = {10.25972/OPUS-25201}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-252015}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2024}, abstract = {In der Initiationsphase der akuten Graft-versus-Host Erkrankung (GvHD) werden CD4+ T-Zellen in den lymphatischen Organen durch h{\"a}matopoietische Antigen-pr{\"a}sentierende Zellen aktiviert. Im Gegensatz dazu, werden in der Effektorphase CD4+ T-Zellen von nicht-h{\"a}matopoetischen Zellen im D{\"u}nndarm aktiviert. Wir stellten die Hypothese auf, dass alloreaktive CD4+ T-Zellen nach allogener h{\"a}matopoetischer Zelltransplantation, welche in der Initiationsphase der aGvHD vorwiegend in die sekund{\"a}ren lymphatischen Organe migrieren, dort durch nicht-h{\"a}matopoetische Lymphknoten-Stromazellen {\"u}ber die Erkennung von MHC-Klasse II aktiviert werden. Um diese Hypothese zu testen, setzten wir ein von allogenen CD4+ T-Zellen-abh{\"a}ngiges MHC Major Mismatch aGvHD Mausmodell ein, um diese Zusammenh{\"a}nge n{\"a}her zu erforschen. Mittels Biolumineszenz-Bildgebung und dreidimensionale Lichtblattmikroskopie und Durchflusszytometrie-Analysen von fr{\"u}heren Zeitpunkten nach einer alloHCT bzw. im Anfangsstadium der aGvHD konnten wir zeigen, dass allogene T-Zellen exklusiv in die Milz, Lymphknoten und die Peyerschen Plaques migrieren und nicht in die intestinale Lamina propria. Indem wir transgene Mauslinien verwendeten, die keine oder eine nur partielle komplette h{\"a}matopoietische Antigenpr{\"a}sentation aufwiesen, konnten wir eine sehr fr{\"u}h auf die alloHCT folgende allogene CD4+ T-Zellaktivierung in den lymphoiden Organen von MHCIIΔCD11c and MHCIIΔ Knochenmark-Chim{\"a}ren nachweisen. Aufgrund des, bei den MHCIIΔ Knochenmarks-Chim{\"a}ren auftretenden Versagens der negativen Thymusselektion und die daraus resultierende autoreaktive Immunreaktionen nach einer syngenen HCST stellte sich heraus, dass dies ein ungeeignetes Modell f{\"u}r die Untersuchung der Pr{\"a}sentation nicht-h{\"a}matopoetischer Antigene bei GvHD ist. Um diese Herausforderung zu bew{\"a}ltigen, generierten wir MHCIIΔVav1 M{\"a}use bei denen die MHC-Klasse-II-Expression auf allen h{\"a}matopoetischen Zellen fehlt. MHCIIΔVav1 M{\"a}use entwickelten eine aGvHD, wobei die Lymphknoten-Stromazellen dieser Tiere allogene CD4+ T-Zellen in gemischten Lymphozytenreaktionen aktivieren konnten. Ebenso konnten mesenteriale Lymphknoten von CD11c.DTR-M{\"a}usen, die zuvor in eine MHCIIΔ Maus transplantiert wurden, CD4+ T-Zellen in vivo aktivieren, wodurch die Lymphknoten-Stromazellen eindeutig als nicht-h{\"a}matopoetische Antigen-pr{\"a}sentierende Zellen der lymphoiden Organe nachgewiesen werden konnten. {\"U}ber das Cre/loxP-System konnten wir Knockout-M{\"a}use mit fehlender MHCII-Expression in Subpopulationen von Lymphknoten-Stromazellen generieren und verwendeten dann Einzelzell-RNA-Sequenzierung. Hier w{\"a}hlten wir Ccl19 und VE-Cadherin aus, um unsere Analyse spezifisch auf die fibroblastischen retikul{\"a}ren Zellen bzw. Endothelzellen der Lymphknoten zu konzentrieren. Bei MHCIIΔCcl19 M{\"a}usen war die Aktivierung alloreaktiver CD4+ T-Zellen in der Initiationsphase der aGvHD m{\"a}ßig reduziert, w{\"a}hrend das Fehlen von MHCII auf den fibroblastischen retikul{\"a}ren Zellen zu einer Hyperaktivierung allogener CD4+ T-Zellen f{\"u}hrte, was wiederum eine schlechtere {\"U}berlebensrate der M{\"a}use zur Folge hatte. Dieser Ph{\"a}notyp wurde durch regulatorische T-Zellen moduliert, die in der Lage waren, H2-Ab1fl M{\"a}use von den Folgen von GvHD zu retten, jedoch nicht die MHCIIΔCcl19. Ein Knock-out von MHCII auf Endothelzellen von MHCIIΔVE-Cadherin M{\"a}usen, f{\"u}hrte in der Initiationsphase der GvHD nur zu einer m{\"a}ßig reduzierten Aktivierung von CD4+ T-Zellen. Umgekehrt zeigten MHCIIΔVE-Cadherin M{\"a}use im Langzeit{\"u}berleben jedoch einen protektiven Ph{\"a}notyp verglichen mit wurfgeschwister H2-Ab1fl M{\"a}usen. Um die Bedeutung der MHCII-Antigenpr{\"a}sentation der Endothelzellen zu untersuchen, generierten wir außerdem MHCIIΔVE-CadherinΔVav1 M{\"a}use, bei welchen eine Antigenpr{\"a}sentation, weder im endothelialen noch im h{\"a}matopoetischen Kompartiment m{\"o}glich war. Lymphknoten-Stromazellen von MHCIIΔVE-CadherinΔVav1 M{\"a}usen waren nicht in der Lage, alloreaktive CD4+ T-Zellen in einer gemischten Lymphozytenreaktion zu aktivieren. Insgesamt konnten wir zum ersten Mal beweisen, dass die MHC-Klassse II auf den Lymphknoten-Stromazellen eine entscheidende Rolle bei der Modulation allogener CD4+ T-Zellen in der Initiations- und schließlich in der Effektorphase der Graft-versus-Host-Disease spielt.}, subject = {Transplantat-Wirt-Reaktion}, language = {en} } @article{SchanbacherHermannsLorenzetal.2023, author = {Schanbacher, Constanze and Hermanns, Heike M. and Lorenz, Kristina and Wajant, Harald and Lang, Isabell}, title = {Complement 1q/tumor necrosis factor-related proteins (CTRPs): structure, receptors and signaling}, series = {Biomedicines}, volume = {11}, journal = {Biomedicines}, number = {2}, issn = {2227-9059}, doi = {10.3390/biomedicines11020559}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-304136}, year = {2023}, abstract = {Adiponectin and the other 15 members of the complement 1q (C1q)/tumor necrosis factor (TNF)-related protein (CTRP) family are secreted proteins composed of an N-terminal variable domain followed by a stalk region and a characteristic C-terminal trimerizing globular C1q (gC1q) domain originally identified in the subunits of the complement protein C1q. We performed a basic PubMed literature search for articles mentioning the various CTRPs or their receptors in the abstract or title. In this narrative review, we briefly summarize the biology of CTRPs and focus then on the structure, receptors and major signaling pathways of CTRPs. Analyses of CTRP knockout mice and CTRP transgenic mice gave overwhelming evidence for the relevance of the anti-inflammatory and insulin-sensitizing effects of CTRPs in autoimmune diseases, obesity, atherosclerosis and cardiac dysfunction. CTRPs form homo- and heterotypic trimers and oligomers which can have different activities. The receptors of some CTRPs are unknown and some receptors are redundantly targeted by several CTRPs. The way in which CTRPs activate their receptors to trigger downstream signaling pathways is largely unknown. CTRPs and their receptors are considered as promising therapeutic targets but their translational usage is still hampered by the limited knowledge of CTRP redundancy and CTRP signal transduction.}, language = {en} } @article{LangZaitsevaWajant2022, author = {Lang, Isabell and Zaitseva, Olena and Wajant, Harald}, title = {FcγRs and their relevance for the activity of anti-CD40 antibodies}, series = {International Journal of Molecular Sciences}, volume = {23}, journal = {International Journal of Molecular Sciences}, number = {21}, issn = {1422-0067}, doi = {10.3390/ijms232112869}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290458}, year = {2022}, abstract = {Simple Summary Targeting of CD40 with antibodies attracts significant translational interest. While inhibitory CD40 targeting appears particularly attractive in the field of organ transplantation and for the treatment of autoimmune diseases, stimulatory CD40 targeting is the aim in tumor immunotherapy and vaccination against infectious pathogens. It turned out that lack of FcγR-binding is the crucial factor for the development of safe and well-tolerated inhibitory anti-CD40 antibodies. In striking contrast, FcγR-binding is of great importance for the CD40 stimulatory capacity of the majority of anti-CD40 antibodies. Typically, anti-CD40 antibodies only robustly stimulate CD40 when presented by FcγRs. However, FcγR-binding of anti-CD40 antibodies also triggers unwanted activities such as destruction of CD40 expressing cells by ADCC or ADCP. Based on a brief discussion of the mechanisms of CD40 activation, we give an overview of the ongoing activities in the development of anti-CD40 antibodies under special consideration of attempts aimed at the development of anti-CD40 antibodies with FcγR-independent agonism or FcγR subtype selectivity. Abstract Inhibitory targeting of the CD40L-CD40 system is a promising therapeutic option in the field of organ transplantation and is also attractive in the treatment of autoimmune diseases. After early complex results with neutralizing CD40L antibodies, it turned out that lack of Fcγ receptor (FcγR)-binding is the crucial factor for the development of safe inhibitory antibodies targeting CD40L or CD40. Indeed, in recent years, blocking CD40 antibodies not interacting with FcγRs, has proven to be well tolerated in clinical studies and has shown initial clinical efficacy. Stimulation of CD40 is also of considerable therapeutic interest, especially in cancer immunotherapy. CD40 can be robustly activated by genetically engineered variants of soluble CD40L but also by anti-CD40 antibodies. However, the development of CD40L-based agonists is biotechnologically and pharmacokinetically challenging, and anti-CD40 antibodies typically display only strong agonism in complex with FcγRs or upon secondary crosslinking. The latter, however, typically results in poorly developable mixtures of molecule species of varying stoichiometry and FcγR-binding by anti-CD40 antibodies can elicit unwanted side effects such as antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP) of CD40 expressing immune cells. Here, we summarize and compare strategies to overcome the unwanted target cell-destroying activity of anti-CD40-FcγR complexes, especially the use of FcγR type-specific mutants and the FcγR-independent cell surface anchoring of bispecific anti-CD40 fusion proteins. Especially, we discuss the therapeutic potential of these strategies in view of the emerging evidence for the dose-limiting activities of systemic CD40 engagement.}, language = {en} } @article{ZaitsevaHoffmannOttoetal.2022, author = {Zaitseva, Olena and Hoffmann, Annett and Otto, Christoph and Wajant, Harald}, title = {Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy}, series = {Frontiers in Pharmacology}, volume = {13}, journal = {Frontiers in Pharmacology}, issn = {1663-9812}, doi = {10.3389/fphar.2022.935086}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290238}, year = {2022}, abstract = {Fibroblast growth factor-inducible 14 (Fn14) is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and is activated by its ligand TNF-like weak inducer of apoptosis (TWEAK). The latter occurs as a homotrimeric molecule in a soluble and a membrane-bound form. Soluble TWEAK (sTWEAK) activates the weakly inflammatory alternative NF-κB pathway and sensitizes for TNF-induced cell death while membrane TWEAK (memTWEAK) triggers additionally robust activation of the classical NF-κB pathway and various MAP kinase cascades. Fn14 expression is limited in adult organisms but becomes strongly induced in non-hematopoietic cells by a variety of growth factors, cytokines and physical stressors (e.g., hypoxia, irradiation). Since all these Fn14-inducing factors are frequently also present in the tumor microenvironment, Fn14 is regularly found to be expressed by non-hematopoietic cells of the tumor microenvironment and most solid tumor cells. In general, there are three possibilities how the tumor-Fn14 linkage could be taken into consideration for tumor therapy. First, by exploitation of the cancer associated expression of Fn14 to direct cytotoxic activities (antibody-dependent cell-mediated cytotoxicity (ADCC), cytotoxic payloads, CAR T-cells) to the tumor, second by blockade of potential protumoral activities of the TWEAK/Fn14 system, and third, by stimulation of Fn14 which not only triggers proinflammtory activities but also sensitizes cells for apoptotic and necroptotic cell death. Based on a brief description of the biology of the TWEAK/Fn14 system and Fn14 signaling, we discuss the features of the most relevant Fn14-targeting biologicals and review the preclinical data obtained with these reagents. In particular, we address problems and limitations which became evident in the preclinical studies with Fn14-targeting biologicals and debate possibilities how they could be overcome.}, language = {en} } @article{MedlerKuckaWajant2022, author = {Medler, Juliane and Kucka, Kirstin and Wajant, Harald}, title = {Tumor necrosis factor receptor 2 (TNFR2): an emerging target in cancer therapy}, series = {Cancers}, volume = {14}, journal = {Cancers}, number = {11}, issn = {2072-6694}, doi = {10.3390/cancers14112603}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-275143}, year = {2022}, abstract = {Despite the great success of TNF blockers in the treatment of autoimmune diseases and the identification of TNF as a factor that influences the development of tumors in many ways, the role of TNFR2 in tumor biology and its potential suitability as a therapeutic target in cancer therapy have long been underestimated. This has been fundamentally changed with the identification of TNFR2 as a regulatory T-cell (Treg)-stimulating factor and the general clinical breakthrough of immunotherapeutic approaches. However, considering TNFR2 as a sole immunosuppressive factor in the tumor microenvironment does not go far enough. TNFR2 can also co-stimulate CD8\(^+\) T-cells, sensitize some immune and tumor cells to the cytotoxic effects of TNFR1 and/or acts as an oncogene. In view of the wide range of cancer-associated TNFR2 activities, it is not surprising that both antagonists and agonists of TNFR2 are considered for tumor therapy and have indeed shown overwhelming anti-tumor activity in preclinical studies. Based on a brief summary of TNFR2 signaling and the immunoregulatory functions of TNFR2, we discuss here the main preclinical findings and insights gained with TNFR2 agonists and antagonists. In particular, we address the question of which TNFR2-associated molecular and cellular mechanisms underlie the observed anti-tumoral activities of TNFR2 agonists and antagonists.}, language = {en} } @article{VargasWagnerShaikhetal.2022, author = {Vargas, Juan Gamboa and Wagner, Jennifer and Shaikh, Haroon and Lang, Isabell and Medler, Juliane and Anany, Mohamed and Steinfatt, Tim and Mosca, Josefina Pe{\~n}a and Haack, Stephanie and Dahlhoff, Julia and B{\"u}ttner-Herold, Maike and Graf, Carolin and Viera, Estibaliz Arellano and Einsele, Hermann and Wajant, Harald and Beilhack, Andreas}, title = {A TNFR2-Specific TNF fusion protein with improved in vivo activity}, series = {Frontiers in Immunology}, volume = {13}, journal = {Frontiers in Immunology}, issn = {1664-3224}, doi = {10.3389/fimmu.2022.888274}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-277436}, year = {2022}, abstract = {Tumor necrosis factor (TNF) receptor-2 (TNFR2) has attracted considerable interest as a target for immunotherapy. Indeed, using oligomeric fusion proteins of single chain-encoded TNFR2-specific TNF mutants (scTNF80), expansion of regulatory T cells and therapeutic activity could be demonstrated in various autoinflammatory diseases, including graft-versus-host disease (GvHD), experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). With the aim to improve the in vivo availability of TNFR2-specific TNF fusion proteins, we used here the neonatal Fc receptor (FcRn)-interacting IgG1 molecule as an oligomerizing building block and generated a new TNFR2 agonist with improved serum retention and superior in vivo activity. Methods Single-chain encoded murine TNF80 trimers (sc(mu)TNF80) were fused to the C-terminus of an in mice irrelevant IgG1 molecule carrying the N297A mutation which avoids/minimizes interaction with Fcγ-receptors (FcγRs). The fusion protein obtained (irrIgG1(N297A)-sc(mu)TNF80), termed NewSTAR2 (New selective TNF-based agonist of TNF receptor 2), was analyzed with respect to activity, productivity, serum retention and in vitro and in vivo activity. STAR2 (TNC-sc(mu)TNF80 or selective TNF-based agonist of TNF receptor 2), a well-established highly active nonameric TNFR2-specific variant, served as benchmark. NewSTAR2 was assessed in various in vitro and in vivo systems. Results STAR2 (TNC-sc(mu)TNF80) and NewSTAR2 (irrIgG1(N297A)-sc(mu)TNF80) revealed comparable in vitro activity. The novel domain architecture of NewSTAR2 significantly improved serum retention compared to STAR2, which correlated with efficient binding to FcRn. A single injection of NewSTAR2 enhanced regulatory T cell (Treg) suppressive activity and increased Treg numbers by > 300\% in vivo 5 days after treatment. Treg numbers remained as high as 200\% for about 10 days. Furthermore, a single in vivo treatment with NewSTAR2 upregulated the adenosine-regulating ectoenzyme CD39 and other activation markers on Tregs. TNFR2-stimulated Tregs proved to be more suppressive than unstimulated Tregs, reducing conventional T cell (Tcon) proliferation and expression of activation markers in vitro. Finally, singular preemptive NewSTAR2 administration five days before allogeneic hematopoietic cell transplantation (allo-HCT) protected mice from acute GvHD. Conclusions NewSTAR2 represents a next generation ligand-based TNFR2 agonist, which is efficiently produced, exhibits improved pharmacokinetic properties and high serum retention with superior in vivo activity exerting powerful protective effects against acute GvHD.}, language = {en} } @article{AidoZaitsevaWajantetal.2021, author = {Aido, Ahmed and Zaitseva, Olena and Wajant, Harald and Buzgo, Matej and Simaite, Aiva}, title = {Anti-Fn14 antibody-conjugated nanoparticles display membrane TWEAK-like agonism}, series = {Pharmaceutics}, volume = {13}, journal = {Pharmaceutics}, number = {7}, issn = {1999-4923}, doi = {10.3390/pharmaceutics13071072}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-242710}, year = {2021}, abstract = {Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the "activating" effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications.}, language = {en} } @article{IsbernerKrausGrigoleitetal.2021, author = {Isberner, Nora and Kraus, Sabrina and Grigoleit, G{\"o}tz Ulrich and Aghai, Fatemeh and Kurlbaum, Max and Zimmermann, Sebastian and Klinker, Hartwig and Scherf-Clavel, Oliver}, title = {Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial}, series = {Cancer Chemotherapy and Pharmacology}, volume = {88}, journal = {Cancer Chemotherapy and Pharmacology}, number = {6}, issn = {1432-0843}, doi = {10.1007/s00280-021-04351-w}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-266476}, pages = {973-983}, year = {2021}, abstract = {Purpose Knowledge on Ruxolitinib exposure in patients with graft versus host disease (GvHD) is scarce. The purpose of this prospective study was to analyze Ruxolitinib concentrations of GvHD patients and to investigate effects of CYP3A4 and CYP2C9 inhibitors and other covariates as well as concentration-dependent effects. Methods 262 blood samples of 29 patients with acute or chronic GvHD who were administered Ruxolitinib during clinical routine were analyzed. A population pharmacokinetic model obtained from myelofibrosis patients was adapted to our population and was used to identify relevant pharmacokinetic properties and covariates on drug exposure. Relationships between Ruxolitinib exposure and adverse events were assessed. Results Median of individual mean trough serum concentrations was 39.9 ng/mL at 10 mg twice daily (IQR 27.1 ng/mL, range 5.6-99.8 ng/mL). Applying a population pharmacokinetic model revealed that concentrations in our cohort were significantly higher compared to myelofibrosis patients receiving the same daily dose (p < 0.001). Increased Ruxolitinib exposure was caused by a significant reduction in Ruxolitinib clearance by approximately 50\%. Additional comedication with at least one strong CYP3A4 or CYP2C9 inhibitor led to a further reduction by 15\% (p < 0.05). No other covariate affected pharmacokinetics significantly. Mean trough concentrations of patients requiring dose reduction related to adverse events were significantly elevated (p < 0.05). Conclusion Ruxolitinib exposure is increased in GvHD patients in comparison to myelofibrosis patients due to reduced clearance and comedication with CYP3A4 or CYP2C9 inhibitors. Elevated Ruxolitinib trough concentrations might be a surrogate for toxicity.}, language = {en} } @article{KuckaLangZhangetal.2021, author = {Kucka, Kirstin and Lang, Isabell and Zhang, Tengyu and Siegmund, Daniela and Medler, Juliane and Wajant, Harald}, title = {Membrane lymphotoxin-α\(_2\)β is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist}, series = {Cell Death \& Disease}, volume = {12}, journal = {Cell Death \& Disease}, number = {4}, doi = {10.1038/s41419-021-03633-8}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-260077}, pages = {360}, year = {2021}, abstract = {In the early 1990s, it has been described that LTα and LTβ form LTα\(_2\)β and LTαβ\(_2\) heterotrimers, which bind to TNFR1 and LTβR, respectively. Afterwards, the LTαβ\(_2\)-LTβR system has been intensively studied while the LTα\(_2\)β-TNFR1 interaction has been ignored to date, presumably due to the fact that at the time of identification of the LTα\(_2\)β-TNFR1 interaction one knew already two ligands for TNFR1, namely TNF and LTα. Here, we show that LTα\(_2\)β interacts not only with TNFR1 but also with TNFR2. We furthermore demonstrate that membrane-bound LTα\(_2\)β (memLTα\(_2\)β), despite its asymmetric structure, stimulates TNFR1 and TNFR2 signaling. Not surprising in view of its ability to interact with TNFR2, LTα\(_2\)β is inhibited by Etanercept, which is approved for the treatment of rheumatoid arthritis and also inhibits TNF and LTα.}, language = {en} }